淋巴瘤治疗中期^(18)F-FDG PET检查的临床应用价值  

Value of Midtreatment ^(18)F-FDP PET in Monitoring Response to Therapy and Prediction Outcome in Lymphoma

作　　者：张红宇[1] 孟庆祥[1] 柳金[1] 庞丽萍[1] 王钧[1] 许蕾[1] 冯佳[1] 张文丽[1] 张倩[1] 孙丽华[1] 钟凤鸾[1] 徐海婵[1] 虞积仁[1] 

机构地区：[1]北京大学深圳医院血液科,广东深圳518036

出　　处：《中国临床医学》2009年第2期309-311,共3页Chinese Journal of Clinical Medicine

摘　　要：目的:探讨在淋巴瘤治疗中期18氟-氟代脱氧葡萄糖-正电子发射计算机断层显像(fluorine-18 fluorodeoxyglucose positron emission tomography,18F-FDP PET/CT)检查的临床应用价值。方法:回顾分析43例淋巴瘤患者治疗中期18F-FDPPET/CT检测淋巴结和结外病变的结果,并与同期CT、B超影像结果进行比较,并结合淋巴结、骨髓活检及生化结果,评价其对早期临床疗效的评价和对预后的预测价值。结果:治疗中期18F-FDP PET/CT共检测15例有残留病灶,此15例临床均未获得完全缓解。同期CT和B超检查29例共32处有残留肿块,除其中同时伴PET阳性的有9例全部复发,另20例得到完全缓解(HD5例,NHL15例);另有8例PET和CT或B超均为阴性,期中2例复发;此外还对6例PET/CT显示阴性但CT、B超检查显示阳性患者的浅表淋巴结进行了2次活检,病理结果均显示为非淋巴瘤组织。比例风险模型(COX)分析显示中期PET阳性为疾病复发或进展的独立预后不良因素(P<0.01)。结论:PET/CT对肿块性质判定较传统影像有显著的优势,治疗中期PET/CT检查对早中期疗效判断和临床预后有显著的临床意义。Objective：To evaluate midtreatment ^18F-FDP PET in monitoring response to therapy and prediction outcome in Lymphoma.Methods：Retrospective analysis forty-three patients with lymphoma who underwent FDG-PET scan after four cycles of chemotherapy, it was also compared with computed tomography（CT）,B ultrasonic and bone marrow biopsy to investigate lymph node/extranodal manifestations. Results：After four cycles of chemotherapy,15 patients had positive FDG-PET and all of them progressed or relapsed, 9 of 26 patients had positive CT or B ultrasonic progressed, 6 patients with FDG-PET -negative but CT-positive underwent second biopsy and pathologic result show no lymphoma evidences. Survival analyses showed midtreatment ^18F-FDP PET-positive was independent risk factors of disease progression.Conclusion： Midtreatment ^18F-FDP PET is a sensitive and specific technique in detecting residual masses of lymphoma and in assessment to therapy, midtreatment 18F-FDP PET is a strong and independent predictor of progression-free survival.

关 键 词：淋巴瘤 氟代脱氧葡萄糖 正电子发射计算机断层显像 

分 类 号：R733[医药卫生—肿瘤]